Boston Scientific Settlement Upped

Natick, MA-based Boston Scientific (NYSE: BSX) announced this morning that it will pay up to $240 million to cover 8,550 patient claims related to defibrillators from Guidant, which Boston Scientific acquired last year. This settlement is expanded from a $195 million agreement announced in July, and covers “substantially all currently asserted claims in the United States” related to a series of recalls and warnings on the Guidant devices.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy